FLT3 and acute myeloid leukemia: A retrospective analysis of older adults (median age 69 years) with FLT3-mutated AML treated with a FLT3i and a hypomethylating agent (azacitidine or decitabine) combined with VEN reported increased CR/CRi rates (93% vs. 70%), measurable residual disease (MRD) negativity rates (FLT3-ITD polymerase chain reaction: 96% vs. 54%, p-value < 0.01; multiparameter flow cytometry [MFC]: 83% vs. 38%, p-value < 0.01), and OS (median not reached vs. 9.5 months, p-value < 0.01) compared to patients treated with doublet regimens combining a FLT3i with lower-intensity chemotherapy [32].